SeaCrest Wealth Management LLC Buys 493 Shares of Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

SeaCrest Wealth Management LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,263 shares of the company’s stock after buying an additional 493 shares during the period. SeaCrest Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $4,030,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. NTV Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 22.8% during the fourth quarter. NTV Asset Management LLC now owns 24,982 shares of the company’s stock valued at $2,044,000 after purchasing an additional 4,643 shares in the last quarter. Crawford Investment Counsel Inc. increased its stake in shares of Merck & Co., Inc. by 1.0% during the fourth quarter. Crawford Investment Counsel Inc. now owns 982,973 shares of the company’s stock valued at $80,407,000 after purchasing an additional 9,909 shares in the last quarter. Whittier Trust Co. increased its stake in shares of Merck & Co., Inc. by 2.7% during the fourth quarter. Whittier Trust Co. now owns 383,660 shares of the company’s stock valued at $31,383,000 after purchasing an additional 9,905 shares in the last quarter. Toronto Dominion Bank increased its stake in shares of Merck & Co., Inc. by 2.9% during the fourth quarter. Toronto Dominion Bank now owns 2,742,219 shares of the company’s stock valued at $143,758,000 after purchasing an additional 77,688 shares in the last quarter. Finally, Hennessy Advisors Inc. increased its stake in shares of Merck & Co., Inc. by 18.8% during the fourth quarter. Hennessy Advisors Inc. now owns 104,500 shares of the company’s stock valued at $8,548,000 after purchasing an additional 16,500 shares in the last quarter. 72.86% of the stock is owned by institutional investors.

Shares of Merck & Co., Inc. stock traded down $0.05 on Tuesday, hitting $74.88. 272,706 shares of the company’s stock were exchanged, compared to its average volume of 10,548,566. The company has a 50-day simple moving average of $79.00 and a 200-day simple moving average of $80.98. The stock has a market capitalization of $189.45 billion, a PE ratio of 16.58, a PEG ratio of 1.89 and a beta of 0.43. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $87.80. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Wednesday, February 3rd. The company reported $1.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.38 by ($0.06). The firm had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.65 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.16 earnings per share. On average, analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 7th. Stockholders of record on Monday, March 15th will be given a dividend of $0.65 per share. The ex-dividend date is Friday, March 12th. This represents a $2.60 annualized dividend and a dividend yield of 3.47%. Merck & Co., Inc.’s payout ratio is 50.10%.

A number of brokerages have weighed in on MRK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Mizuho reiterated a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a report on Sunday, December 6th. SVB Leerink increased their price target on shares of Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, November 10th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $95.36.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Read More: Understanding dividend yield and dividend payout ratio

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.